
FDA Approves Zirabev, Biosimilar to Avastin Clinical Oncology News
The FDA approved bevacizumab-bvzr (Zirabev, Pfizer), a biosimilar to bevacizumab (Avastin, Genentech), for the treatment of five types of cancer: metastatic …
“colorectal cancer” – Google News
